GO:0043548 phosphatidylinositol 3-kinase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043548 phosphatidylinositol 3-kinase binding describes the molecular function of selectively interacting with a phosphatidylinositol 3-kinase (PI3K) enzyme, a core node in phosphoinositide signaling.
• PI3K binding proteins act as spatial and temporal regulators that recruit PI3K to membranes, scaffold signaling complexes, or modulate catalytic activity.
• The interaction is central to diverse processes including insulin signaling, immune cell function, and cancer progression.
• Dysregulated PI3K binding contributes to tumorigenesis, immune evasion, and metabolic disorders, making it a therapeutic target.
• CRISPR knockout, point mutation, and knock-in models enable precise dissection of PI3K binding interfaces and their downstream effects.
• Understanding GO:0043548 requires integrating structural biology, live-cell imaging, and functional genomics.
Description
Phosphatidylinositol 3-kinase binding (GO:0043548) is a molecular function defined as the selective interaction with any enzyme that catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring. This binding event is a critical step in phosphoinositide signaling, enabling PI3K enzymes to be recruited to specific cellular membranes and to generate lipid second messengers such as phosphatidylinositol 3,4,5-trisphosphate (PIP3). The function is mediated by conserved structural domains, including Src homology 2 (SH2) domains, pleckstrin homology (PH) domains, and proline-rich motifs, which recognize activated PI3K or its regulatory subunits. Researchers study GO:0043548 because it governs the spatial and temporal control of PI3K signaling, which is essential for normal physiology and is frequently hijacked in disease. For example, in T regulatory cells, lipid signaling enforces functional specialization within tumors, while in bladder cancer, PI3K/Akt activation downstream of G3BP1 and SLU7 promotes immune evasion. The binding function also links the Ras and PI3K pathways to nucleocytoplasmic transport through Ran-binding protein 3 phosphorylation. This article provides a comprehensive overview of GO:0043548, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods including CRISPR-based models. All statements are grounded in verified PubMed literature to support publication-ready research and generative-AI retrieval.
phosphatidylinositol 3-kinase binding At A Glance
| GO ID | GO:0043548 |
|---|---|
| GO term | phosphatidylinositol 3-kinase binding |
| Ontology | molecular_function |
| Synonym | phosphoinositide 3-kinase binding; PI3K binding |
| Major function | Selective interaction with PI3K enzymes to regulate phosphoinositide signaling |
| Definition source | QuickGO |
| Related enzymes | PI3K class I, II, and III isoforms |
| Common domains | SH2, PH, proline-rich, and Ras-binding domains |
What Is GO:0043548?
GO:0043548 phosphatidylinositol 3-kinase binding is a molecular function term describing the binding to a phosphatidylinositol 3-kinase, any enzyme that catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring. In practice, this means a protein or domain physically interacts with a PI3K enzyme, often via modular interaction domains, to regulate its localization, activity, or substrate access.
Why Is phosphatidylinositol 3-kinase binding Important in Cell Biology?
GO:0043548 is important because PI3K binding proteins serve as critical regulators of a signaling axis that controls cell growth, survival, metabolism, and immune responses. Dysregulation of these interactions is a hallmark of many cancers, where aberrant PI3K recruitment drives tumorigenesis and immune evasion. Moreover, PI3K binding is essential for normal insulin signaling and glucose homeostasis, and its perturbation contributes to metabolic disorders. Understanding this function at the molecular level informs drug discovery, as selective inhibitors of PI3K isoforms and their binding partners are actively being developed.
• Controls recruitment of PI3K to membranes, a prerequisite for PIP3 generation and downstream AKT activation.
• Regulates insulin signaling and glucose uptake through interactions with insulin receptor substrates.
• Modulates T regulatory cell function in tumors, influencing immune suppression.
• Facilitates bacterial survival within host cells, as shown for Rickettsia typhi Risk1 effector.
• Links Ras and PI3K pathways to nucleocytoplasmic transport via Ran-binding protein 3.
• Contributes to cancer immune evasion by downregulating MHC-I through PI3K/Akt activation.
• Serves as a target for selective inhibitors of PI3K C2α and other isoforms.
• Provides a mechanistic basis for understanding corneal epithelium homeostasis and wound healing.
• Enables structural studies that reveal allosteric and orthosteric binding sites.
• Offers opportunities for CRISPR-based functional genomics to identify novel binding regulators.
Molecular Mechanism of phosphatidylinositol 3-kinase binding
Domain-mediated recognition of PI3K
In simple terms: Proteins use specialized domains to grab onto PI3K enzymes.
The binding function GO:0043548 is typically mediated by conserved modular domains such as SH2, PH, and proline-rich regions that recognize phosphorylated tyrosines or lipid headgroups on PI3K or its regulatory subunits. For example, the p85 regulatory subunit of class IA PI3K contains SH2 domains that bind to phosphotyrosine motifs on activated receptor tyrosine kinases, thereby recruiting the catalytic p110 subunit to the membrane. Structural studies of PI3K C2α have revealed how its helical and kinase domains coordinate membrane interaction and substrate binding.
Membrane recruitment and complex assembly
In simple terms: Binding brings PI3K to the right place at the right time.
Once a PI3K-binding protein engages the enzyme, it often anchors the complex to specific membrane compartments, such as the plasma membrane or endosomes. This spatial regulation ensures that PI3K phosphorylates its lipid substrates in the correct context, leading to localized PIP3 production. In Rickettsia typhi, the effector Risk1 binds PI3K to promote intracellular survival, illustrating how pathogens exploit this function.
Allosteric and catalytic regulation
In simple terms: Binding can switch PI3K activity on or off.
PI3K binding proteins can modulate the catalytic activity of PI3K allosterically. For instance, binding of the p85 subunit to p110 inhibits basal activity, while phosphotyrosine peptide binding relieves this inhibition. Selective inhibitors of PI3K C2α have been developed that exploit structural features of the enzyme to block its function, highlighting the druggability of these interfaces.
Downstream signaling and feedback
In simple terms: The binding event triggers a cascade that can loop back.
Following PI3K binding and activation, downstream effectors such as AKT are recruited to the membrane via their PH domains, leading to phosphorylation cascades that control cell survival and proliferation. Feedback loops, including those involving mTOR and S6K, can phosphorylate insulin receptor substrates and dampen PI3K binding, providing a mechanism for signal termination. In T regulatory cells, lipid signaling enforces functional specialization, partly through PI3K-dependent pathways.
Nucleocytoplasmic transport linkage
In simple terms: PI3K binding can influence transport into the nucleus.
Ran-binding protein 3 phosphorylation links the Ras and PI3K pathways to nucleocytoplasmic transport, demonstrating that PI3K binding proteins can regulate nuclear import and export. This expands the functional repertoire of GO:0043548 beyond membrane signaling to include nuclear events.
Key Genes Involved in GO:0043548 phosphatidylinositol 3-kinase binding
The following genes and proteins are central to phosphatidylinositol 3-kinase binding (GO:0043548) and its regulatory network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PIK3CA | Encodes p110α catalytic subunit of PI3K; binds p85 and Ras | Frequently mutated in cancer; target for inhibitors |
| PIK3R1 | Encodes p85α regulatory subunit; SH2-mediated binding to phosphotyrosines | Regulates PI3K activity; mutations in insulin resistance |
| PIK3C2A | Class II PI3K C2α; binds membrane and protein partners | Structural and inhibitor studies |
| AKT1 | PH domain binds PIP3; downstream effector | Mediates survival signaling; cancer target |
| IRS1 | Insulin receptor substrate; binds p85 to activate PI3K | Insulin signaling and metabolic disease |
| RANBP3 | Ran-binding protein 3; phosphorylated by Ras/PI3K pathways | Links PI3K to nucleocytoplasmic transport |
| G3BP1 | RNA-binding protein; activates PI3K/Akt in bladder cancer | Immune evasion and MHC-I downregulation |
| SLU7 | Splicing factor; cooperates with G3BP1 to activate PI3K/Akt | Bladder cancer immune evasion |
| FOXP3 | Transcription factor in Tregs; influenced by lipid signaling | Tumor immune suppression |
| PTEN | Lipid phosphatase; opposes PI3K by dephosphorylating PIP3 | Tumor suppressor; negative regulator of PI3K binding |
| RAS | Small GTPase; binds PI3K and activates it | Oncogene; links to RANBP3 phosphorylation |
| Risk1 | Rickettsia typhi effector; binds PI3K | Bacterial survival in host cells |
| PDPK1 | Kinase that binds PIP3 and activates AKT | Downstream of PI3K binding |
| MTOR | Kinase in mTORC1/2; feedback regulation of PI3K | Metabolic and cancer signaling |
| RICTOR | Component of mTORC2; phosphorylates AKT | PI3K pathway crosstalk |
| TSC1/2 | Tumor suppressors; regulated by AKT | Feedback to PI3K signaling |
| S6K1 | Ribosomal protein S6 kinase; feedback phosphorylates IRS1 | Desensitizes PI3K binding |
How Is phosphatidylinositol 3-kinase binding Regulated?
Phosphatidylinositol 3-kinase binding is regulated at multiple levels. Post-translational modifications, such as phosphorylation of IRS1 by S6K1, can reduce the interaction between IRS1 and p85, thereby dampening PI3K activation. Lipid phosphatases like PTEN dephosphorylate PIP3, indirectly affecting the duration of PI3K binding at the membrane. Additionally, the phosphorylation of Ran-binding protein 3 by Ras/PI3K pathways modulates nucleocytoplasmic transport, illustrating crosstalk between signaling and transport machinery. Allosteric regulation by binding partners and feedback loops involving mTOR complex 1 are also critical for fine-tuning this function.
phosphatidylinositol 3-kinase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIK3CA | Cancer (breast, colorectal, bladder) | Knock-in of activating mutations in cell lines |
| PTEN | Cancer, metabolic syndrome | Knockout in cancer cell lines |
| IRS1 | Type 2 diabetes, insulin resistance | Point mutation of phosphorylation sites |
| G3BP1/SLU7 | Bladder cancer immune evasion | Knockout in bladder cancer cells |
| RANBP3 | Nucleocytoplasmic transport dysregulation | Phospho-mutant knock-in |
Cancer
Dysregulated PI3K binding is a hallmark of many cancers. Activating mutations in PIK3CA or loss of PTEN lead to constitutive PI3K signaling, promoting tumor growth and survival. In bladder cancer, G3BP1 and SLU7 jointly promote immune evasion by downregulating MHC-I via PI3K/Akt activation, highlighting how PI3K binding proteins can drive immune escape. Selective inhibitors of PI3K C2α are being developed to target these pathways.
Metabolic disorders
Insulin signaling relies on the binding of IRS1 to the p85 regulatory subunit of PI3K, which is essential for glucose uptake. Defects in this interaction contribute to insulin resistance and type 2 diabetes. Feedback phosphorylation of IRS1 by S6K1 provides a mechanism for desensitization under conditions of chronic insulin exposure.
Infectious disease
The bacterial effector Risk1 from Rickettsia typhi binds PI3K to promote intracellular survival, demonstrating that pathogens can exploit GO:0043548 for their own benefit. Understanding these interactions may inform new antimicrobial strategies.
Immune regulation
In tumor-infiltrating T regulatory cells, lipid signaling enforces functional specialization, partly through PI3K-dependent pathways. This suggests that PI3K binding proteins could be targeted to modulate immune responses in cancer immunotherapy.
From phosphatidylinositol 3-kinase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate PI3K binding? | CRISPR knockout in HEK293 or cancer cell lines |
| What is the effect of a specific phosphorylation site on PI3K binding? | Point mutation knock-in via CRISPR |
| Can a disease-associated mutation alter PI3K binding affinity? | Knock-in of patient mutations |
| Where does PI3K binding occur in live cells? | Tagged knock-in with fluorescent protein |
| Does overexpression of a binding partner drive transformation? | Overexpression in primary or immortalized cells |
| Can we identify novel PI3K binding proteins? | CRISPR library screening with readouts for PI3K activity |
How to Study the phosphatidylinositol 3-kinase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of PI3K-binding protein complexes | Inhibitor design |
| Cryo-EM | Conformational dynamics of PI3K complexes | Membrane-associated assembly |
| Live-cell imaging | Spatiotemporal recruitment of PI3K | Membrane targeting |
| AP-MS | Protein-protein interactions | Identification of novel binders |
| BioID | Proximity-dependent biotinylation | Mapping interactome in live cells |
| CRISPR knockout screens | Gene essentiality for PI3K signaling | Discovery of regulators |
| Phosphoproteomics | Changes in phosphorylation downstream of PI3K | Pathway activation |
| Ribo-seq | Translation efficiency of PI3K-related genes | mRNA translation control |
Structural biology
X-ray crystallography and cryo-EM have elucidated the structural basis of PI3K C2α function and its interaction with binding partners. These methods reveal atomic details of the binding interface, informing inhibitor design.
Live-cell imaging
Fluorescently tagged PI3K and binding proteins can be visualized using confocal or TIRF microscopy to track recruitment to membranes in real time. This approach provides spatiotemporal insights into GO:0043548.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) and proximity labeling (BioID) can identify novel PI3K binding partners and map interaction networks. These methods are essential for discovering new components of the PI3K signaling complex.
Functional genomics
CRISPR knockout screens and RNA interference can systematically test the requirement of candidate genes for PI3K binding and downstream signaling. Combined with phosphoproteomics, these approaches reveal signaling rewiring.
How CRISPR Can Be Used to Study GO:0043548 phosphatidylinositol 3-kinase binding
Knockout
CRISPR knockout of genes encoding PI3K subunits or binding partners can abolish specific interactions and reveal their contribution to downstream signaling. For example, knocking out PIK3CA or PIK3R1 in cancer cell lines reduces PIP3 production and AKT activation.
Point Mutation
Introducing point mutations that disrupt phosphorylation sites or binding interfaces (e.g., in IRS1 or RANBP3) allows precise testing of their role in PI3K binding. This approach is ideal for dissecting signaling mechanisms without confounding effects of protein loss.
Knock-in
Knock-in of disease-associated mutations (e.g., PIK3CA activating mutations) or epitope tags enables studies of mutant PI3K binding in a physiological context. Tagged knock-in also facilitates imaging and proteomic analysis.
Overexpression
Overexpression of a candidate PI3K binding protein can drive pathway activation and transformation, as shown for G3BP1 and SLU7 in bladder cancer. This approach is useful for gain-of-function studies and identifying oncogenic drivers.
How EDITGENE Supports phosphatidylinositol 3-kinase binding Research
Researchers studying phosphatidylinositol 3-kinase binding-related genes often need to determine whether a candidate gene is causally involved in PI3K recruitment, activation, or downstream signaling. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylinositol 3-kinase binding research.
Frequently Asked Questions About phosphatidylinositol 3-kinase binding
What is phosphatidylinositol 3-kinase binding?
It is a molecular function (GO:0043548) defined as the selective interaction with a phosphatidylinositol 3-kinase enzyme, which catalyzes the addition of a phosphate group to an inositol lipid at the 3' position.
What genes are involved in phosphatidylinositol 3-kinase binding?
Key genes include PIK3CA, PIK3R1, PIK3C2A, IRS1, AKT1, RANBP3, G3BP1, SLU7, and PTEN, among others.
How does PI3K binding regulate cell signaling?
Binding recruits PI3K to membranes, enabling PIP3 generation and activation of downstream effectors like AKT, which control survival, growth, and metabolism.
What diseases are associated with abnormal PI3K binding?
Cancer, insulin resistance, infectious diseases, and immune disorders are linked to dysregulated PI3K binding.
What methods are used to study phosphatidylinositol 3-kinase binding?
Structural biology, live-cell imaging, proteomics, and CRISPR-based functional genomics are commonly used.
How can CRISPR help study PI3K binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes to test their role in PI3K binding and signaling.
What is the role of PTEN in PI3K binding?
PTEN is a lipid phosphatase that dephosphorylates PIP3, thereby opposing PI3K signaling and indirectly regulating PI3K binding.
Is PI3K binding involved in immune evasion?
Yes, in bladder cancer, G3BP1 and SLU7 promote immune evasion by downregulating MHC-I via PI3K/Akt activation.
What are the structural domains that mediate PI3K binding?
SH2, PH, proline-rich, and Ras-binding domains are common mediators of PI3K binding.
How does insulin signaling relate to PI3K binding?
Insulin receptor substrates like IRS1 bind the p85 subunit of PI3K, activating the pathway to promote glucose uptake.
Conclusion
GO:0043548 phosphatidylinositol 3-kinase binding is a fundamental molecular function that orchestrates phosphoinositide signaling in health and disease. Its roles span insulin signaling, immune regulation, cancer progression, and host-pathogen interactions. Advances in structural biology and CRISPR-based models continue to unravel the precise mechanisms and therapeutic potential of targeting PI3K binding interfaces. EDITGENE provides comprehensive CRISPR services to support researchers in dissecting PI3K binding biology, from knockout and point mutation models to library screening and bioinformatics. By leveraging these tools, the field can accelerate the translation of mechanistic insights into novel therapeutics.
References
- 1. Yoon SO et al.. 2023. Ran-Binding Protein 3 Phosphorylation Links the Ras and PI3-Kinase Pathways to Nucleocytoplasmic Transport.. Mol Cell 83(22):4190 PMID: 37980093
- 2. Lo WT et al.. 2022. Structural basis of phosphatidylinositol 3-kinase C2α function.. Nat Struct Mol Biol 29(3):218-228 PMID: 35256802
- 3. Chen K et al.. 2022. The role of the PI3K/AKT signalling pathway in the corneal epithelium: recent updates.. Cell Death Dis 13(5):513 PMID: 35641491
- 4. Lo WT et al.. 2023. Development of selective inhibitors of phosphatidylinositol 3-kinase C2α.. Nat Chem Biol 19(1):18-27 PMID: 36109648
- 5. Voss OH et al.. 2020. Risk1, a Phosphatidylinositol 3-Kinase Effector, Promotes Rickettsia typhi Intracellular Survival.. mBio 11(3) PMID: 32546622
- 6. Lim SA et al.. 2021. Lipid signalling enforces functional specialization of T(reg) cells in tumours.. Nature 591(7849):306-311 PMID: 33627871
- 7. Thiel G et al.. 2021. Insulin-Responsive Transcription Factors.. Biomolecules 11(12) PMID: 34944530
- 8. Zheng X et al.. 2024. G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K/Akt Activation in Bladder Cancer.. Adv Sci (Weinh) 11(7):e2305922 PMID: 38084438
